[Efficacy of second-line treatment based on moxifloxacin triple therapy for Helicobacter pylori infection].
OBJECTIVE
To evaluate the efficacy and tolerability of moxifloxacin-based triple therapy as an alternative second-line treatment for Helicobacter pylori (H. pylori) infection.


METHODS
A total of 109 patients, in whom the initial standard PPI triple therapy had failed to eradicate Hp infection, were included. Patients were randomized to one of the following 7-day treatment regimens: (1) rabeprazole 10 mg twice a day, moxifloxacin 400 mg/day and amoxicillin 1000 mg twice a day; and (2) rabeprazole 10 mg twice a day, bismuth salts 150 mg three times a day; clarithromycin 500 mg twice a day, metronidazole 400 mg twice a day. The eradication rates and side-effect rates of these two regimens were compared.


RESULTS
The eradication rates were 75.5% (40/53) and 83.3% (40/48) with moxifloxacin-based triple therapy, and 62.5% (35/56) and 71.4% (35/49) with bismuth-based quadruple therapy by intention-to-treat and per-protocol analyses (both P > 0.05) respectively.


CONCLUSIONS
The 7-day moxifloxacin-based triple therapy has a high eradication rate with fewer side-effects. This regimen can be a safe and effective option as second-line treatment for H. pylori infection.
Zheng
Xiao-li
XL
Department of Gastroenterology, Beijing Hospital, Beijing 100730, China. zhengxiaoli2006@yahoo.cn
Xu
Le
L
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001372:Aza Compounds / Q000008:administration & dosage* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D024841:Fluoroquinolones; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D011804:Quinolines / Q000008:administration & dosage* / Q000627:therapeutic use; D017211:Treatment Failure; D055815:Young Adult
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin